TABLE 2.
MICs of antimicrobials for carbapenemase-producing organisms harboring newly identified bla GES genes, and their transformants a
| Antimicrobial agents | MICs (μg/mL) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| bla GES-47 | bla GES-48 | bla GES-49 | bla GES-50 | bla GES-51 | bla GES-54 | — | |||||||
|
K. michiganensis
2CC1 |
E. coli
NEB10-beta |
A. A. caviae
2CC8 |
E. coli
NEB10-beta |
A. A. veronii bv. veronii6BC9 |
E. coli
NEB10-beta |
K. michiganensis
10BC5 |
E. coli
NEB10-beta |
C. portucalensis 10CC7 |
E. coli
NEB10-beta |
E. kobei
6BC5 |
E. coli
NEB10-beta |
E. coli
NEB10-beta |
|
| Ampicillin | >16 | >16 | >16 | >16 | >16 | >16 | >16 | >16 | >16 | >16 | >16 | >16 | ≤2 |
| Piperacillin | >64 | >64 | 16 | >64 | >64 | >64 | 32 | 64 | 64 | 32 | 32 | 32 | ≤4 |
| SAM | >16–8 | >16–8 | >16–8 | >16–8 | >16–8 | >16–8 | >16–8 | >16–8 | >16–8 | >16–8 | >16–8 | >16–8 | ≤2–1 |
| TZP | >64–4 | >64–4 | 16-4 | 32–4 | >64–4 | 64–4 | 8-4 | 8-4 | 16-4 | 32–4 | 16-4 | 8-4 | ≤4–4 |
| Cefazolin | >16 | >16 | >16 | >16 | >16 | >16 | >16 | >16 | >16 | >16 | >16 | >16 | 1 |
| Cefotiam | >4 | >4 | >4 | >4 | >4 | >4 | 4 | >4 | >4 | >4 | >4 | >4 | ≤0.5 |
| Ceftazidime | >16 | 4 | 8 | 16 | >16 | >16 | 2 | 2 | 4 | 8 | 16 | >16 | ≤0.5 |
| Cefpodoxime | >4 | >4 | >4 | >4 | >4 | >4 | ≤1 | >4 | >4 | >4 | 4 | >4 | ≤1 |
| Ceftriaxone | 4 | ≤1 | 16 | 8 | 16 | 8 | ≤1 | ≤1 | 2 | 2 | 2 | 4 | ≤1 |
| Cefepime | 4 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 |
| Cefmetazole | >32 | 32 | >32 | >32 | >32 | >32 | 16 | 32 | >32 | 32 | >32 | 32 | ≤1 |
| Flomoxef | >16 | 8 | >16 | >16 | >16 | >16 | >16 | >16 | >16 | >16 | 16 | 16 | ≤2 |
| Aztreonam | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 |
| Imipenem | 2 | 0.5 | ≤0.25 | 2 | 2 | 0.5 | 0.5 | 2 | 4 | 2 | ≤0.25 | 0.5 | ≤0.25 |
| Meropenem | 4 | 0.25 | 0.5 | 1 | 1 | 0.5 | 0.25 | 1 | 4 | 0.5 | 0.5 | 0.5 | ≤0.12 |
| Gentamicin | ≤2 | ≤2 | ≤2 | 4 | 8 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 |
| Amikacin | ≤8 | ≤8 | ≤8 | ≤8 | ≤8 | ≤8 | ≤8 | 32 | ≤8 | ≤8 | ≤8 | ≤8 | ≤8 |
| Minocycline | ≤2 | ≤2 | ≤2 | ≤2 | 4 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | 8 | ≤2 | ≤2 |
| Levofloxacin | 0.5 | ≤0.12 | 1 | ≤0.12 | 1 | ≤0.12 | 0.5 | ≤0.12 | 0.5 | ≤0.12 | 1 | ≤0.12 | ≤0.12 |
| Fosfomycin | ≤32 | ≤32 | 64 | ≤32 | ≤32 | ≤32 | ≤32 | ≤32 | ≤32 | ≤32 | 128 | ≤32 | ≤32 |
| SXT | ≤9.5–0.5 | ≤9.5–0.5 | 19-1 | ≤9.5–0.5 | >38/2 | ≤9.5–0.5 | ≤9.5–0.5 | ≤9.5–0.5 | ≤9.5–0.5 | ≤9.5–0.5 | 19-1 | ≤9.5–0.5 | ≤9.5–0.5 |
a
MIC, minimum inhibitory concentration; SAM, ampicillin-sulbactam; SXT, sulfamethoxazole-trimethoprim; TZP, piperacillin-tazobactam.